PremiumRatingsPromising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec Genelux announces alignment with FDA of approval pathway for Olvi-Vec PremiumThe FlyBiotech Alert: Searches spiking for these stocks today Biotech Alert: Searches spiking for these stocks today Genelux reports Q3 EPS (19c), consensus (19c) PremiumThe FlyGenelux initiated with a Buy at Guggenheim Genelux:1st patient dosed in VIRO-25 trial with Olvi-Vec in NSCLC Genelux initiated with a Buy at Roth MKM 
